ALKBH5 and neoplasm: Research by Li et al. found that writers (such as METTL3 and METTL14) suppress T cell functions by enhancing the expression of immune checkpoints (PD-L1) and promoting glycolysis, leading to immunotherapy resistance; meanwhile, erasers (such as FTO and ALKBH5) maintain tumor stem cell characteristics and an immunosuppressive microenvironment by lowering m6A modification levels, weakening the effects of immunotherapy.